Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Revenue of Lucid Diagnostics Inc. (LUCD)
Revenue in 2023 (TTM): $2.43 M
According to Lucid Diagnostics Inc.'s latest financial reports the company's current revenue (TTM) is $2.43 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Lucid Diagnostics Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $2.43 M | $-6,050,000 | $-49,751,000 | $-52,666,000 | $-52,666,000 |
| 2022 | $377 K | $-3,237,000 | $-54,235,000 | $-56,171,000 | $-56,171,000 |
| 2021 | $500 K | $-85,000 | $-27,415,000 | $-28,078,000 | $-28,737,000 |
| 2020 | $ | $ | $482 | $-8,279,517 | $-8,279,517 |
| 2019 | $ | $ | $ | $-4,420,544 | $-4,420,544 |
| 2018 | $ | $ | $562.96 K | $-1,125,914 | $-1,125,914 |